About

Welcome to MadStockPicks.com. Hey there !! I am Rob and along with my Investing Guru brother Mike, we have passionately been trading and investing in stocks for a combined 20+ years. We strive to bring you the best in Stock Picking, Stock Tips and Investing and Trading Advice.

And we want to go out of our way to give you the best resources in finding that much sought after Success in the Stock market.

Its not an easy landscape to make money in Stocks and can be downright challenging. We hope to make it a little easier for you with our Site here.

Thanks for dropping by !! :)

One Comment


  1. L. Rubinstein says:
    Wednesday at 12:41 am

    Hello

    What is your opinion about Bioniche life sciences ( Bnc.to) (see post below) ??

    Thank you very much in advance .

    Regards
    L.Rubinstein

    Bioniche Life Sciences (BNC.TO)

    Market Cap: 84 Mil $
    Cash: 22 Mil $
    Price: 1,17 $

    Buy Rating by Dundee Securities

    Bioniche has three businesses with diversified risk/reward profiles:Animal Health, which is expected to generate around $28 million in salesin fiscal 2010; Human Health, with Phase 3 results expected in mid-2010from lead product, Urocidin, testing for bladder cancer; and FoodSafety, with Canadian approval and a conditional license pending in theU.S. of a vaccine for reducing E. coli 0157 in cattle feces, and apipeline of other vaccines.

    Mr. Martin points out that Urocidin provides the “biggest upsidepotential” for Bioniche investors. His initial diligence suggests thatUrocidin has a “relatively high overall probability of approval,” eventhough the first of two planned Phase 3 trials has a moderate level ofrisk, as the refractory patients enrolled in the trial are a“tougher-to-treat” population than was enrolled in the Phase 2 trial, hesays.

    Mitigating the risk somewhat is the 20% “complete response” hurdlerequired for Phase 3. That compares with the company’s Phase 2 results,where patients achieved a 46.4% CR rate at 26 weeks in a population thatwas mainly relapsed but also included a few patients being treated forthe first time.

    A second planned Phase 3 trial will test Urocidin head-to-head againstthe current standard of care, baccilus Calmette-Guerin (BCG) infirst-line treatment, “where we expect Urocidin to demonstrate betterefficacy, based on prior data, and superior safety and tolerability,” hepredicts.

    In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to EndoPharmaceuticals. Based on incidence of bladder cancer and possiblepricing, he figures the global market opportunity for Urocidin in therefractory population could be $800 million. If the second Phase 3 trialexpands the Urocidin label to first-line treatment, the marketopportunity could grow to an estimated $2 billion.

    “Twenty-five percent penetration of this market would represent $500million in annual sales and an estimated $112.5 million in gross profitfor Bioniche,” Mr. Martin says .

    ——————————————————————–

    Bioniche to Get up to $130M in Urology Deal with Endo
    http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=51437

    Crystal Research 18.02.2010
    http://www.crystalra.com/pdf/BNC_2QFY10_Update_02-18-10.pdf

    Urocidin Potential New Treatment for Bladder Cancer
    http://www.associatedcontent.com/article/1939454/urocidin_potential_new_treatment_for_pg3.html?cat=70

    Upcoming Milestones 2010

    2009/2010 Conditional license for E. coli cattle vaccine in the U.S.

    2009/2010 Achievement of pre-commercialization milestone payments for
    UrocidinTM

    2010 First U.S. sales of E. coli cattle vaccine

    2010 Results of refractory Phase III bladder cancer trial

    2011 Belleville, ON vaccine manufacturing centre operational

Leave a Reply